The following changes were made: [1] The Leibovich scoring system as an eligibility criterion was replaced; [2] The study population was broadened; [3] The intended sample size was adjusted; [4] The definition of a DFS event included new primary renal cell carcinoma (RCC); [5] Radiographic scans performed as part of surveillance for RCC recurrence would be submitted to central assessment for potential independent review; [6] A sample of RCC tumor with the highest tumor grade would be submitted for central review; [7] A safety evaluation visit was added at 3 months after the last dose of study treatment; [8] Detailed guidelines for investigator determination of RCC disease recurrence were added; [9] Updated safety data from a Phase Ia Study was included in the protocol; [10] DFS in participants whose tumors express IHC IC1/2/3 was added as a secondary endpoint; [11] Randomization stratification factors were changed to reflect the updated participant population; [12] The number of study sites increased; [13] Instructions for emergency unblinding of treatment assignment were provided; [14] The definition of a positive surgical margin was clarified; [15] Guidance was provided regarding the eligibility of participants with small pulmonary nodules; [16] Exclusion criteria were updated; [17] The frequency of surveillance imaging for RCC recurrence was reduced; [18] Clarification was made regarding thyroid-function testing; [19] Epstein-Barr Virus (EBV) screening sample collection was removed; [20] The timing of patient-reported outcome evaluations was clarified; [21] The instructions for the reporting of infusion-related reactions were modified; [22] The back-up Medical Monitor changed; [23] The definition of sarcomatoid RCC was clarified; [24] Additional minor changes were made to improve clarity and consistency.

The following changes were made: [1] The method of assessment of the primary endpoint was changed; [2] It was specified that tumor assessments should continue until disease recurrence; [3] Assessment of imaging data by independent central radiologic review was required for confirmation of disease-free status at baseline; [4] The frequency of surveillance imaging for RCC recurrence after Year 4 was increased from annually to every 6 months; [5] Clarification that the level of stratification factors could be combined for analysis purposes; [6] Clarification that prospective protocol deviations were not allowed; [7] Pregnancy testing frequency was increased to every cycle and at the first post-treatment visit; [8] Details of the Medical Monitor and back-up Medical Monitor were updated; [9] The imaging and biopsy requirements for confirmation of disease recurrence were updated; [10] Additional minor changes were made to improve clarity and consistency.

The following updates were made: [1] Section 5.1.1 was amended to align with current atezolizumab risk language; [2] Appendix 11 was added so there was no longer a need to consult the Atezolizumab Investigator's Brochure for management guidelines; [3] Additional minor changes were made to improve clarity and consistency.

The following changes were made: [1] The control (placebo) arm median disease-free survival (mDFS) assumption was modified from 36 to 47 months, and the control arm median overall survival (OS) assumption was modified from 81.4 to 100 months; [2] Eligibility criteria was modified; [3] The role of the independent Data Monitoring Committee (iDMC) was amended; [4] 1- and 2-year IRF-assessed DFS rate and 1- and 2-year investigator-assessed DFS rate were added as secondary efficacy endpoints; [5] Inclusion criterion were modified; [6] The exclusionary time periods were amended; [7] Information regarding blinding of treatment assignment and circumstances for unblinding were updated; [8]

The following changes were made: [1] Specified when ECG recordings were required; [2]2 Exclusion criterion were clarified; [3] Stated that premedication is "not routinely recommended" instead of “not permitted;” [4] Median disease-free survival (mDFS) assumption of the control arm was amended; [5] It was clarified that the Unblinded Medical Monitor would not be directly involved in the conduct of the clinical study; [6] The control arm mDFS and OS assumptions were modified; [7] Eligibility criteria were modified; [8] The role of the independent Data Monitoring Committee was amended; [9] 1- and 2-year IRF-assessed DFS rate and 1- and 2-year investigator-assessed DFS rate were added as secondary efficacy endpoints; [10] The exclusionary time periods were amended; [11] Information regarding blinding of treatment and unblinding was updated; [12] Clarification was made regarding the administration of infusions and timing of vital sign measurements relative; [13] Clarification of various assessments; [14] Clarification regarding timepoints for completion of patient-reported outcome questionnaires; [15] Instructions about participant withdrawal from the RBR after site closure were modified; [16] Lists of risks for atezolizumab and guidelines for managing participants who experience atezolizumab-associated AEs was revised; [17] Information regarding systemic immune activation was amended; [18] The reporting of the term “sudden death” was updated; [19] Event reporting for hospitalization was clarified; [20] Back-up and Unblinded Medical Monitor information was updated; [21] Additional language was added or updated for clarification; [22] Guidelines for the assessment of renal cell carcinoma- were amended; [23] Additional minor changes were made to improve clarity and consistency.

The following changes were made: [1] "Immune-related" was changed to "immune-mediated" when describing events associated with atezolizumab; [2] Exploratory study objectives were updated; [3] Language was added for clarification; [4] The list of atezolizumab risks was updated; [5] Systemic immune activation was replaced by hemophagocytic lymphohistiocytosis and macrophage activation syndrome in the list of potential risks for atezolizumab; [6] Medical Monitor information was updated; [7] Clarification was provided on the reporting of all deaths after the AE reporting period; [8] Definition of local recurrence was updated; [9] Additional details were provided on the planned exploratory subgroup analysis of participants with tumor Fuhrman Grade 4 or sarcomatoid histology; [10] The requirement for use of a tourniquet was removed; [11] The atezolizumab AE management guidelines were revised; [12] The management guidelines for infusion-related reactions associated with atezolizumab were updated; [13] Guidelines for managing participants who experienced atezolizumab-associated AE were revised to include myositis; [14] Additional minor changes were made to improve clarity and consistency.

The following changes were made: [1] Language was added to clarify endpoints associated with secondary efficacy and exploratory objectives; [2] Statistical methods updated to remove the planned interim DFS analysis and to update the total OS analyses; [3] COVID-specific information and risk language was included; [4] Clarified that the iDMC scope of evaluation was for safety data only; [5] Clarified that unblinding of treatment assignment would occur after the primary analysis of DFS; [6] Language in relation to AE reporting associated with PRO data was removed; [7] Back-up medical monitor information was updated; [8] Detailed updates associated with the removal of the planned interim DFS analysis; [9] Incorporate language associated with a sensitivity analysis that will be conducted for IRF-assessed DFS; [10] Atezo protocol SCAR language updated; [11] HLH and MAS replaced systemic inflammatory response syndrome on the list of atezolizumab-associated AEs of special interest (AESIs); [12] The management guidelines for HLH and MAS were modified; [13] Clarified that AEs associated with a special situation that also qualify as AESIs should be reported within 24 hours; [14] Clarified that sites are not expected to review the PRO data for AEs; [15] Female participants were to inform the investigator if they became pregnant per ICF instructions; [16] Correction to the Roche policy on data sharing; [17] The list of approved indications for atezolizumab was updated; [18] The management guidelines for Grade 4 myositis were removed; [19] ATA (anti-therapeutic antibody) was updated to ADA (anti-drug antibody); [20] "Immunerelated" was changed to "immune-mediated" when describing events associated with atezolizumab; [21] Additional minor changes were made to improve clarity and consistency.

The following changes were made: [1] The protocol was amended to change the primary endpoint of IRF-assessed DFS to investigator-assessed DFS; [2] Benefit-risk assessment and guidance on concomitant administration of coronavirus disease 2019 vaccines with atezolizumab were modified; [3] Language was updated to change the endpoint of IRF-assessed DFS to investigator-assessed DFS; [4] The secondary efficacy endpoint of investigator-assessed DFS was changed to IRF-assessed DFS; [5] A new secondary endpoint of IRF-assessed event-free survival (EFS) was added; [6] The endpoint for immunogenicity objective, “To evaluate the immune response to atezolizumab” was updated; [7] The definition of “Distant metastasis-free survival” in secondary efficacy objective endpoint was updated; [8] One exploratory endpoint was removed; [9] The responsibilities of the Principal Investigator and the role of the Medical Monitor were clarified; [10] Language was updated to clarify the use of public record searches for survival follow-up following withdrawal of consent; [11] The Medical Monitor information was updated; [12] The name of “Serious Adverse Events (SAE)/AESI Reporting Form” was updated; [13] Language was updated to include time to clinically confirmed deterioration analysis to allow for analyzing all FKSI-19 data captured; [14] The medical term “primary biliary cirrhosis” was replaced by the term “primary biliary cholangitis;" [15] The adverse event management guidelines was updated; [16] The management guidelines referencing Grade 4 myositis were removed; [17] Additional minor changes were made to improve clarity and consistency.